S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Oramed Pharmaceuticals Stock Forecast, Price & News

-0.09 (-2.02 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $4.37
50-Day Range
MA: $4.31
52-Week Range
Now: $4.37
Volume246,881 shs
Average Volume173,108 shs
Market Capitalization$103.46 million
P/E RatioN/A
Dividend YieldN/A
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Oramed Pharmaceuticals logo


Overall MarketRank

1.32 out of 5 stars

Medical Sector

580th out of 1,558 stocks

Pharmaceutical Preparations Industry

296th out of 638 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ORMP



Sales & Book Value

Annual Sales$2.70 million
Cash Flow$1.28 per share
Book Value$1.12 per share


Net Income$-14,350,000.00
Net Margins-230.07%


Market Cap$103.46 million
Next Earnings Date4/5/2021 (Estimated)
-0.09 (-2.02 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

How has Oramed Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ORMP stock has increased by 32.0% and is now trading at $4.37.
View which stocks have been most impacted by COVID-19

Is Oramed Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oramed Pharmaceuticals stock.
View analyst ratings for Oramed Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Oramed Pharmaceuticals?

Wall Street analysts have given Oramed Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oramed Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, April 5th 2021.
View our earnings forecast for Oramed Pharmaceuticals

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its quarterly earnings data on Wednesday, January, 13th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.09. Oramed Pharmaceuticals had a negative return on equity of 28.75% and a negative net margin of 230.07%.
View Oramed Pharmaceuticals' earnings history

What price target have analysts set for ORMP?

3 Wall Street analysts have issued 1-year target prices for Oramed Pharmaceuticals' shares. Their forecasts range from $5.50 to $17.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $11.17 in the next year. This suggests a possible upside of 155.5% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Oramed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the following people:
  • Mr. Nadav Kidron, Pres, CEO & Exec. Director (Age 46, Pay $1.2M)
  • Mr. Avraham Gabay, CFO, Treasurer & Sec. (Age 35, Pay $191.06k)
  • Mr. Joshua Hexter, Chief Operating & Bus. Officer (Age 50, Pay $267.82k)
  • Dr. Miriam Kidron, Chief Scientific Officer & Director (Age 80, Pay $389.19k)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $4.37.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $103.46 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is www.oramed.com.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.